Lumosa Therapeutics Co., Ltd. (TPEX: 6535)
Taiwan
· Delayed Price · Currency is TWD 247.00
-1.00 (-0.40%)
Sep 10, 2024, 1:30 PM CST
Lumosa Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -280.72 | -238.04 | -494.66 | 95.95 | -322.56 | -240.94 | Upgrade
|
| Depreciation & Amortization | 16.35 | 23.1 | 21.92 | 32.02 | 35.63 | 39.16 | Upgrade
|
| Other Amortization | 0.16 | 0.26 | 0.25 | 0.08 | - | 0.17 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | - | 0 | Upgrade
|
| Asset Writedown & Restructuring Costs | 10.37 | 10.37 | - | 102.52 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -47.09 | -119.08 | 217.4 | -627.61 | -24.5 | -46.15 | Upgrade
|
| Stock-Based Compensation | 22.21 | 8.59 | 5.03 | 3.22 | - | 0.1 | Upgrade
|
| Provision & Write-off of Bad Debts | -1.32 | 0.15 | - | - | - | - | Upgrade
|
| Other Operating Activities | -16.98 | -19.75 | -9.18 | 0.1 | -12.9 | 13.37 | Upgrade
|
| Change in Accounts Receivable | 10.15 | 1.84 | -4.31 | 7.93 | 261.66 | -263.78 | Upgrade
|
| Change in Inventory | 0.48 | 4.77 | -26.3 | -50.61 | -7.78 | -23.92 | Upgrade
|
| Change in Accounts Payable | 0.24 | 0.5 | -13.51 | 14.47 | -7.81 | 7.84 | Upgrade
|
| Change in Unearned Revenue | -4.04 | -3.85 | 2.2 | -0.32 | 0.32 | 98.4 | Upgrade
|
| Change in Other Net Operating Assets | 6.69 | 2.91 | 0.7 | -30.35 | -51.17 | 36.22 | Upgrade
|
| Operating Cash Flow | -283.51 | -328.21 | -300.46 | -452.6 | -129.11 | -379.52 | Upgrade
|
| Capital Expenditures | -13.34 | -14.32 | -2.29 | -0.09 | -0.68 | - | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | - | 47.25 | Upgrade
|
| Divestitures | - | - | - | - | - | 44.55 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -0.7 | - | -0.49 | - | 16.7 | Upgrade
|
| Investment in Securities | 255.13 | 247.6 | -66.92 | -36.41 | 7.04 | -125.46 | Upgrade
|
| Other Investing Activities | 4 | 8 | - | - | - | 1.44 | Upgrade
|
| Investing Cash Flow | 245.79 | 240.58 | -69.2 | -36.98 | 6.36 | -15.53 | Upgrade
|
| Long-Term Debt Repaid | - | -4.33 | -4.65 | -5.47 | -6.8 | -6.25 | Upgrade
|
| Net Debt Issued (Repaid) | -4.24 | -4.33 | -4.65 | -5.47 | -6.8 | -6.25 | Upgrade
|
| Issuance of Common Stock | - | 0.29 | 0.81 | 436.74 | 859.38 | 13.58 | Upgrade
|
| Other Financing Activities | 0.1 | 0.1 | 50 | - | - | - | Upgrade
|
| Financing Cash Flow | -4.14 | -3.95 | 46.17 | 431.28 | 852.58 | 7.33 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.06 | -0.03 | 0.02 | -0.01 | 0 | 0.2 | Upgrade
|
| Net Cash Flow | -41.81 | -91.6 | -323.47 | -58.32 | 729.83 | -387.52 | Upgrade
|
| Free Cash Flow | -296.85 | -342.53 | -302.74 | -452.69 | -129.79 | -379.52 | Upgrade
|
| Free Cash Flow Margin | -622.16% | -601.81% | -1136.33% | -2607.34% | -599.47% | -220.59% | Upgrade
|
| Free Cash Flow Per Share | -1.83 | -2.11 | -1.86 | -3.00 | -1.07 | -3.24 | Upgrade
|
| Cash Interest Paid | 0.11 | 0.05 | 0.15 | 0.26 | 0.15 | 0.27 | Upgrade
|
| Cash Income Tax Paid | 0.56 | 0.57 | -0.61 | 0.06 | 13.32 | 2.47 | Upgrade
|
| Levered Free Cash Flow | -179.41 | -212.08 | -207.14 | -293.1 | 4.06 | -179.72 | Upgrade
|
| Unlevered Free Cash Flow | -179.34 | -212.05 | -207.05 | -292.94 | 4.15 | -179.55 | Upgrade
|
| Change in Net Working Capital | -12.29 | -5.87 | 40.75 | 58.77 | -182.68 | 141.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.